The stock of Sage Therapeutics Inc. (NASDAQ:SAGE) decreased by -$0.1 on Tuesday to $21.53, down -0.47 percent. The last five days have seen an average of 2,081,785 shares of common stock traded. 17 times new highs were reached in the current year, with a fall of -$16.83. The average number of shares traded over the last 20 days was 2,922,156, while the average volume over the last 50 days totaled 1,647,441.
SAGE stock dropped -53.67% since last month. On 08/07/23, the company’s shares reached a one-month low of $16.51. The stock touched a high of $59.99 on 06/12/23, after rallying from a low of $16.51 in 52 weeks. The price of SAGE stock has declined by -43.56% or -$16.83 this year, reaching a new high 17 times. Still, the stock price is down -64.11% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
SAGE stock investors should be aware that Sage Therapeutics Inc. (SAGE) stock had its last reported insider trading activity 6 days ago on Aug 09. On Aug 09, Director Barrett Elizabeth acquired 2,000 shares at $18.64 each. This transaction resulted in the insider spending $37,279. On May 09, Barrett Elizabeth added 1,000 shares at a price of US$50.50. After the transaction, the insider now owns 1,000 shares. Director JONAS JEFFREY M had earlier sold 11,643 shares on Feb 10 for $44.61 a share. The transaction was completed for $519,413.
Valuation Metrics
Beta for the stock is 1.14. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 110.25, the price-to-book (PB) ratio of 1.31.
Financial Health
For the three months ended June 29, Sage Therapeutics Inc.’s quick ratio was 11.00, while its current ratio was 11.00, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 92.70% percent. Based on annual data, it had gross profit of $6.87 million and revenue of $7.69 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. SAGE’s return on assets (ROA) during the last 12 months has been -46.00%. There was a -43.70% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -49.80%.
Earnings Surprise
According to Sage Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29, it had $881.2 million in cash and short-term investments. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $2.47 million, while revenues rose by 39.27% to $3.29 million. It was predicted that Sage Therapeutics Inc.’s quarterly earnings would be -$2.68, but it ended up being -$2.55, beating the consensus by -5.10%. EBITDA was -$174.52 million for the quarter. At the end of Sage Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 97.91 million, while its total debt was $8.73 million. Equity owned by shareholders amounts to $59.88 million.
Technical Picture
Here’s a quick look at Sage Therapeutics Inc.’s (SAGE) price momentum from a technical perspective. As of 14 August, the RSI 9-day stood at 25.40%, suggesting the stock is oversold, with a 402.19% historical volatility rate.
The stochastic %K and %D were 20.93% and 16.67% respectively, while the average true range (ATR) was 2.66. Based on the 14-day stochastic reading of 23.20%, the RSI (14) reading is 24.39%. On the 9-day MACD Oscillator, the stock is at -1.86, and the 14-day reading is at -6.22.
Analyst Ratings
Sage Therapeutics Inc. (NASDAQ: SAGE) was downgraded by Needham to a a Hold rating in its latest research report. The stock was previously rated as a a Buy. Analysts have assigned Sage Therapeutics Inc. (SAGE) an Hold rating. SAGE is a stock that is recommended for selling by 0 brokerage firms, while 17 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 4 others recommend it as a buy.
What is SAGE’s price target for the next 12 months?
The current consensus forecast for the stock is between $18.00 and $79.00, with a median target price of $22.00. In analyzing these forecasts, the average price target given by analysts for Sage Therapeutics Inc. (SAGE) is $27.82.
